Corifollitropin alfa for poor responders patients, a prospective randomized study

• প্রধান লেখক: F. M. Fusi (Author), L. Zanga (Author), M. Arnoldi (Author), S. Melis (Author), M. Cappato (Author), I. Candeloro (Author), A. Di Pasqua (Author)
• বিন্যাস: গ্রন্থ
• প্রকাশিত: BMC, 2020-07-01T00:00:00Z.
• বিষয়গুলি: article
• অনলাইন ব্যবহার করুন: Connect to this object online.

Abstract Background Poor ovarian response remains one of the biggest challenges for reproductive endocrinologists. The introduction of corifollitropin alpha (CFA) offered an alternative option to other gonadotropins for its longer half-life, its more rapid achievement of the threshold and higher FSH...